Autopsy report · NCT01120275
Gamma-Secretase/Notch Signalling Pathway Inhibitor RO4929097 in Treating Patients With Stage IV Melanoma
Cause of deathOther
“Administratively complete.”
Life of this trial
- Registered 5 months before it started.
- Ran for about 4 years 10 months before it stopped.
- 36 participants enrolled.
- Results were posted on the registry 10 months after it ended.
Vital statistics
- Status
- Terminated
- Phase
- Phase 2
- Sponsor
- National Cancer Institute (NCI)
- Sponsor type
- US National Institutes of Health
- Conditions
- Acral Lentiginous Malignant Melanoma; Lentigo Maligna Malignant Melanoma; Nodular Malignant Melanoma; Recurrent Melanoma; Solar Radiation-related Skin Melanoma; Stage IV Melanoma
- Interventions
- gamma-secretase/Notch signalling pathway inhibitor RO4929097; laboratory biomarker analysis
- Participants
- 36
- Sites
- 178
- Countries
- United States
Look deeper
- The official registry record (the source of truth)
- Record history: every change the sponsor made
- Open it in the database
Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.